QIAGEN launches unique CALR mutation assay for MPN diagnosis
QIAGEN today announced the European launch of a unique CE-IVD marked calreticulin (CALR) mutation assay to aid in establ…
QIAGEN today announced the European launch of a unique CE-IVD marked calreticulin (CALR) mutation assay to aid in establ…
Q2 2013 results: Adjusted net sales of $316.4 million (+3% CER) on growth in all regions; adjusted operating income of $…
. Achieves Q1 2013 targets: Net sales of $303.6 million grow 3% CER on expansion in all regions; adjusted diluted EPS…
. QIAGEN exceeds Q4 and full-year 2012 targets: - Full-year 2012: Net sales advance 10% CER (+7% reported) to $1.…
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today that it exceeded its goal for new placements o…
. - Net sales rise 12% (+13% CER) to $296.4 million, adjusted operating income advances 14% to $80.3 million and adjust…
. - Significant progress on strategic initiatives to drive growth and innovation: - Driving platform success: More…
. - Net sales of $264.3 million (0%, -2% CER) reflect anticipated soft start to 2011, disruptions in Japan and other ma…
QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations for the fourth quar…
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that it has acquired ESE GmbH, a privately he…